GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B1204 Ondansetron hydrochloride dihydrateSummary: 5-HT3 receptor antagonist -
B1359 Formoterol fumarate2 CitationSummary: A long-acting β2-adrenergic receptor agonist -
B1477 Lurasidone HClTarget: 5-HT2 Receptors|D2 Receptors|5-HT1 Receptors|5-HT7 ReceptorsSummary: Dopamine D2/5-HT2A/5-HT7/5-HT1A inhibitor -
B2258 Tropisetron HydrochlorideTarget: 5-HT3 ReceptorsSummary: 5-HT3 receptor antagonist -
B1209 DoxazosinSummary: Quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors -
B1205 FluvoxamineTarget: Serotonin reuptakeSummary: Selective serotonin reuptake inhibitor -
B1206 PizotifenTarget: 5-HT2 ReceptorsSummary: Highly selective 5-HT receptor blocking agent -
B2007 Pizotifen MalateTarget: 5-HT2 Receptors|D2 ReceptorsSummary: 5-HT receptor antagonist -
B1214 PerindoprilTarget: Angiotensin-Converting Enzymes (ACEs)Summary: ACE inhibitor -
B2154 AlprostadilSummary: vasodilator

